FEDERAL COURT OF AUSTRALIA
Pfizer Corp v Commissioner of Patents (No 2) [2006] FCA 1176
PATENTS – date for calculation of extension of term of patents relating to pharmaceutical substances – “first inclusion in the Australian Register of Therapeutic Goods” not limited to regulatory approval to market pharmaceutical substance in Australia – correct date if no “pre-TGA marketing approval” granted is first entry in the Australian Register of Therapeutic Goods, including an entry as listed goods for export only
STATUTORY CONSTRUCTION – extrinsic materials relevant to context and legislative history – materials equivocal on whether “first inclusion” means registration or listing – legislative objective that patentee should have “effective patent life” to exploit patent
WORDS AND PHRASES – “first inclusion in the Australian Register of Therapeutic Goods” – “first regulatory approval date” – “pre-TGA marketing approval”
Patents Act 1990 (Cth) ss 70(1), 70(3), 70(5), 70(6), 77
Patents Regulations 1991 (Cth) reg 10.7(7)
Acts Interpretation Act 1901 (Cth) s 15AB
Therapeutic Goods Act 1989 (Cth) ss 9A, 19A, 25, 26, 31(2) repealed s 17Atlantis Corporation Pty Ltd v Schindler [1997] FCA 455 cited
Doric Products Pty Ltd v Lockwood Security Products Pty Ltd (2002) 54 IPR 495 cited
H LundbeckA/S v Commissioner of Patents (2006) 150 FCR 269 applied
Newcastle City Council v GIO General Limited (1997) 191 CLR 85 applied
Pfizer Corp v Commissioner of Patents (2006) 67 IPR 646 cited
Re Pfizer Corporation (2005) 67 IPR 201 affirmed
Stevens v Kabushiki Kaisha Sony Computer Entertainment (2005) 221 ALR 448 cited
Woolworths Limited v BP plc [2006] FCAFC 132 cited
Woolworths Limited v BP plc (2006) 150 FCR 134 citedPFIZER CORP, PFIZER LTD, PFIZER INC AND PFIZER RESEARCH & DEVELOPMENT COMPANY N.V/SA v COMMISSIONER OF PATENTS AND SPIRIT PHARMACEUTICALS PTY LIMITED (ACN 109 225 747)
NSD 1955 OF 2005
BENNETT J
11 SEPTEMBER 2006
SYDNEY
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
NSD 1955 OF 2005
ON APPEAL FROM THE COMMISSIONER OF PATENTS
BETWEEN:
PFIZER CORP
First ApplicantPFIZER LTD
Second ApplicantPFIZER INC
Third ApplicantPFIZER RESEARCH & DEVELOPMENT COMPANY N.V/SA
Fourth ApplicantAND:
COMMISSIONER OF PATENTS
First RespondentSPIRIT PHARMACEUTICALS PTY LIMITED
(ACN 109 225 747)
Second Respondent
JUDGE:
BENNETT J
DATE OF ORDER:
11 SEPTEMBER 2006
WHERE MADE:
SYDNEY
THE COURT ORDERS THAT:
1.The application, being an appeal from the Commissioner of Patents, is dismissed.
2.The applicants pay the first respondent’s costs.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
NSD 1955 OF 2005
ON APPEAL FROM THE COMMISSIONER OF PATENTS
BETWEEN:
PFIZER CORP
First ApplicantPFIZER LTD
Second ApplicantPFIZER INC
Third ApplicantPFIZER RESEARCH & DEVELOPMENT COMPANY N.V/SA
Fourth ApplicantAND:
COMMISSIONER OF PATENTS
First RespondentSPIRIT PHARMACEUTICALS PTY LIMITED
(ACN 109 225 747)
Second Respondent
JUDGE:
BENNETT J
DATE:
11 SEPTEMBER 2006
PLACE:
SYDNEY
REASONS FOR JUDGMENT
The Patents Act 1990 (Cth) (‘the Act’) provides for the…
Keep reading for free
Create a free CaseChat account to read Pfizer Corp v Commissioner of Patents (No 2) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2006] FCA 1176
- Decision Date
CaseChat Overview and Summary
The court had to decide whether an export-only listing of a patented product in the ARTG constituted the "first inclusion" under section 70 of the Act, thereby affecting the calculation of patent term extensions under section 77. The crux of the legal issue was the interpretation of the statutory language concerning "first inclusion" and "first regulatory approval date," and whether the export-only listing of a patented product in the ARTG could be considered a form of regulatory approval that triggers the commencement of the patent term extension period. Additionally, the court needed to assess the relevance and admissibility of expert evidence from Dr Walter regarding the regulatory requirements for Listed Goods and the extent to which an export-only listing enabled patent exploitation.
The Federal Court held that an inclusion in the ARTG, including an export-only listing as Listed Goods, qualifies as the "first inclusion" for the purposes of section 70 of the Act. The court determined that this inclusion, if it precedes registration for marketing in Australia and no "pre-TGA marketing approval" was given, constitutes the "first inclusion in the ARTG" and the "first regulatory approval date" for calculating the period of extension under section 77. The court dismissed the application on the grounds that the appeal against the Commissioner's decision should not succeed. Furthermore, the court ordered that the applicants pay the costs of the Commissioner, although Spirit Pharmaceuticals, having joined the proceeding as a respondent, had agreed not to seek costs. The court reserved the matter of Pfizer’s application for a stay, its associated costs, and any undertaking regarding damages for further submissions from the parties.
Orders
Orders of the court
1. The application, being an appeal from the Commissioner of Patents, is dismissed.
2. The applicants pay the first respondent’s costs.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Established by: BENNETT J